Two new medical trials counsel the technique could be profitable, whether or not which means switching to a lower-dose GLP-1 injection or tablet.
“Nevertheless folks get their weight down, the physique will struggle to get it again up,” says Richard Siegel, MD, endocrinologist at Tufts Medication Weight + Wellness – Stoneham, in Massachusetts. “There’s a robust chance that the burden will pattern again up except folks take motion. Upkeep dosing is an enormous a part of the plan that must be put in place.”
The correct upkeep dosing “can look completely different for everybody,” in line with Mir Ali, MD, medical director of MemorialCare Surgical Weight Loss Middle at Orange Coast Medical Middle in Fountain Valley, California. However the newest medical trial outcomes ship a framework for healthcare suppliers and their sufferers.
Two GLP-1 Methods Helped Lock in Weight Loss
The brand new research, printed in peer-reviewed medical journals inside a day of one another, have been funded by Eli Lilly, which makes the GLP-1 drugs Zepbound (tirzepatide) and the oral drug Foundayo (orforglipron).
Dropping From a Greater to a Decrease Dose of Tirzepadite
The trial seemed on the security and effectiveness of tirzepatide in two eventualities:
- Persevering with to take tirzepatide on the most tolerated dose (10 or 15 milligrams [mg], relying on the affected person) after preliminary therapy on that dose
- Reducing the dose to five mg after preliminary therapy to keep up weight reduction.
The researchers in contrast each doses in opposition to a placebo.
Key findings:
These Who Stayed on the Most Tolerated Dose After 60 weeks of weight reduction on tirzepatide, individuals who stayed on the identical dose throughout a upkeep stage (52 weeks) stored off all the burden (about 50 kilos).
At the beginning of the trial, they have been 247 kilos, on common; by the top they have been 197.
These Who Dropped to a Low Dose for Upkeep Examine members who decreased their dose to five mg regained a comparatively small quantity of weight (12 kilos, on common) in contrast with the entire quantity they’d misplaced over the prior 60 weeks (nearly 54 kilos).
At the beginning of the trial members have been 250 kilos, on common; by the top they have been 208.
Switching From Injections to a GLP-1 Tablet
The examine discovered that weight regain was comparatively minimal, whether or not topics misplaced weight from injectable semaglutide (Wegovy) or tirzepatide.
On common, sufferers who switched from semaglutide to orforglipron regained about 2 kilos of the burden they misplaced over the course of a yr (nearly 42 kilos whole). At the beginning of the examine they weighed about 250 kilos, on common; by the top they have been about 211.
Those that switched from tirzepatide to orforglipron regained about 11 kilos of the burden they misplaced on common over a yr (nearly 55 kilos whole). At the beginning of the examine they weighed about 255 kilos, on common; by the top they have been about 211.
The Trials Add Information to a Apply Medical doctors Have Already Been Doing
Healthcare suppliers have been prescribing upkeep doses of GLP-1s for years, Dr. Ali says. However there isn’t a variety of knowledge to counsel how a lot weight sufferers can count on to maintain off utilizing completely different drugs.
“Upkeep dosing refers to persevering with therapy after preliminary weight reduction, usually at a decrease dose or a special formulation, to assist preserve the burden off long-term,” explains Nicole Paolini Albanese, PharmD, medical professor within the division of pharmacy apply within the division of training and educating innovation on the College at Buffalo in New York.
Upkeep dosing is often acceptable “when a affected person has reached focused medical or particular person weight reduction objectives and approached a plateau level the place there is no such thing as a lively weight reduction or weight regain,” says Gitanjali Srivastava, MD, medical director of Vanderbilt Weight problems Medication.
Medical doctors could use completely different methods for upkeep dosing primarily based on a affected person’s funds and the way they react to sure drugs, Ali says. “Some will take drugs much less incessantly, some could have a decrease dose,” he says.
Dr. Srivastava notes that he has some sufferers who’ve had success sustaining their weight reduction by taking a GLP-1 medicine as soon as each three months.
Sufferers Might Have the Greatest Outcomes Staying on These Medicines
The trials particularly checked out weight reduction outcomes, however docs say the findings counsel that staying on a upkeep dose of medicine can assist enhancements in coronary heart well being and blood sugar administration.
“The physique is completely different now. Metabolism is extra environment friendly, more practical. Vitality regulatory pathways within the physique have reset,” Srivastava says. However these well being positive aspects could also be erased when somebody stops taking drugs altogether, Ali says.
Dr. Siegel recommends sufferers view upkeep dosing the identical method they’d take into account ongoing medicine for another persistent situation. “Power illnesses want persistent medicine,” he says. “There are some folks with diabetes or weight problems who can preserve [health gains] with life-style. However others might have persistent medicine.”
Examine Limitations to Think about
The trials didn’t comply with the sufferers past a yr of upkeep dosing, making it tough to know what would occur long term. “Whereas useful, decades-long knowledge could be far more necessary, and I am positive they’ll proceed to watch these sufferers,” Dr. Albanese says.
The trial inhabitants was additionally restricted to individuals who responded to the drugs and tolerated them.
Lastly, neither trial checked out life-style options like adjusting food regimen and train. “The one comparator was placebo, and we already knew that stopping these drugs would lead to weight regain,” Albanese says.
Some Upkeep Doses Might Be Cheaper Than Others
The trials didn’t handle pricing, however Ali says it’s usually an element for sufferers on upkeep dosing.
“Price normally relies on a affected person’s insurance coverage plan and the way the affected person is getting the drugs,” he says. “If sufferers are paying out of pocket, normally the dose isn’t that large of an element. If it’s a prescription, it may have an effect on the copay to some extent, however each insurance coverage is completely different.”
Capsules like Foundayo may additionally be cheaper than injectables like tirzepatide, relying on insurance coverage protection, Ali says. Nevertheless, he says there usually isn’t an enormous change in worth between a most tolerated dose of an injectable medicine and a upkeep dose.
“Folks must know that they’ve selections,” Siegel says. “Let your supplier know your objectives and your funds. Full conversations about your wants are going to be necessary in order that the entire choices that may help in upkeep are on the market.”
